Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05859958 · ClinicalTrials.gov registry record
ABO Blood Group Type Association With COVID-19 Severity
A clinical trial, sponsored by Arrowhead Regional Medical Center.
- Completed
- Registry status
- 599
- Enrollment target
NCT05859958 is a clinical trial that has completed, run by Arrowhead Regional Medical Center. The registered enrollment target is 599 participants.
The verdict
NCT05859958 has completed, sponsored by Arrowhead Regional Medical Center.
- COMPLETED
- Registry status
- 599 participants
- Enrollment target
Study Summary
The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2023-05-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05859958
The ClinicalTrials.gov registry entry for NCT05859958 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 599 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrowhead Regional Medical Center, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT05859958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05859958 about?
NCT05859958 is a clinical study titled "ABO Blood Group Type Association With COVID-19 Severity". The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to ...
What is the current status of trial NCT05859958?
This trial is currently completed. The enrollment target is 599 participants. The study started on 2022-11-10. Estimated completion is 2023-05-10.
What interventions are being tested in trial NCT05859958?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05859958?
This trial is sponsored by Arrowhead Regional Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.